Nevro (NYSE:NVRO) today announced that Chair, CEO and President D. Keith Grossman intends to retire this year. Grossman informed the board that he plans to retire from his CEO and president duties in 2023. He intends to do so following the selection of his successor at the spinal cord stimulation (SCS) technology developer. Following the […]
Nevro Corp.
The biggest medtech stock gainers, losers in 2022
In another roller coaster year for medtech, these are the companies that saw their stock rise and fall the most drastically. The MassDevice MedTech 100 Index, which includes stocks of the world’s largest medical device companies, reflects the performance of many in the medtech space. In a tough year for a lot of businesses, the Index […]
FDA approves Nevro HFX iQ spinal cord stimulation
Nevro (NYSE:NVR) announced that the FDA approved its Senza HFX iQ spinal cord stimulation (SCS) system. Redwood City, California-based Nevro designed Senza HFX iQ to use artificial intelligence (AI) to learn from patients. The company says it’s the first such SCS system. It utilizes Nevro’s high-frequency 10 kHz therapy platform. The company developed it to […]
Nevro wins FDA approval for manufacturing operations in Costa Rica
Nevro (NYSE:NVRO) announced that the FDA approved manufacturing operations in Costa Rica for the production of its spinal cord stimulation (SCS) systems. Redwood City, Californa-based Nevro’s new facility sits in the Coyol Free Trade Zone in Alajuela, Costa Rica. It produces proprietary SCS systems that treat chronic pain, including the HFX product platform. The facility […]
Nevro wins multiple coverage options for spinal cord stimulation
Nevro (NYSE:NVRO) today announced positive updates to multiple spinal cord stimulation (SCS) coverage policies. Aetna’s new SCS policy explicitly covers PDN (painful diabetic neuropathy), effective Aug. 29, 2022. Aetna’s health plan covers approximately 22 million commercial lives. Novitas and First Coast, Medicare Administrative Contractors (MACs) that represent 12 states, also provided a positive update. They […]
Boston Scientific to pay Nevro $85M to settle rest of patent litigation
Nevro (NYSE:NVRO) and Boston Scientific (NYSE:BSX) announced today that they reached a settlement over intellectual property litigations. The settlement gives Boston Scientific the freedom to operate using the features and capabilities embodied in its current line of products for frequencies below 1,500 Hz, with Nevro given the freedom to operate using the features and capabilities […]
Nevro rises on Street-beating Q4 sales
Nevro (NYSE:NVRO) shares ticked up today on fourth-quarter results that beat the consensus revenue forecast. The Redwood City, California-based company posted losses of $30.1 million, or -86¢ per share, on sales of $102.8 million for the three months ended Dec. 31, 2021, for a large bottom-line slide deeper into the red on a sales decline […]
Nevro touts 12-month data for 10 kHz spinal cord stimulation
Nevro (NYSE:NVRO) today reported positive 12-month data from the Senza-NSRBP randomized controlled trial of its implantable neurostimulation device for back pain. Redwood City, California–based Nevro’s data, published in Journal of Neurosurgery: Spine, showed that high-frequency 10 kHz spinal cord stimulation (SCS) therapy results in profound improvement in non-surgical refractory back pain (NSRBP) patients in comparison […]
FDA approves expanded labeling for Nevro spinal cord stimulation
Nevro (NYSE:NVRO) today said it received FDA approval for expanded labeling of its Senza spinal cord stimulations system to treat non-surgical refractory back pain (NSRBP). Redwood City, California–based Nevro designed the 10 kHz therapy to improve pain relief and reduce opioid use. The 12-month results from a study of the system showed that patients who […]
UnitedHealthcare to cover Nevro’s spinal cord stimulation treatment for chronic pain
Nevro (NYSE:NVRO) announced today that UnitedHealthcare will provide coverage for its painful diabetic neuropathy (PDN) treatment. Redwood City, California–based Nevro’s Senza 10 kHz spinal cord stimulation (SCS) therapy will now be covered by the largest private health insurance company in the U.S. for dates of service on or after March 1, 2022, according to a […]
How medtech fared in the first waves of the pandemic
Medtech industry revenue, research spending and employment declined in the first year of the COVID-19 pandemic, according to a Medical Design & Outsourcing analysis of financial data. Total sales, R&D spending and employment for the world’s largest medical device companies declined in 2020 and early 2021, according to a Medical Design & Outsourcing analysis tallying the ongoing pandemic’s initial […]